# COCP (Cocrystal Pharma, Inc.) - SEC EDGAR Financial Statements

> Cocrystal Pharma, Inc. reported $6.77M in total assets and a net loss of $11.33M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/COCP
- Markdown: https://convexityos.com/fundamentals/COCP.md
- SEC CIK: 0001412486
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:04 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001412486&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$11.51M | Operating profit |
| Net Income | FY 2025 | -$11.33M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.65 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$8.20M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $4.87M | Total debt: $1.26M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | -- | -- | -- | -- | -- | $2.01M | $6.56M | -- | -- | -- |
| Research & Development | $5.05M | $12.54M | $15.17M | $12.39M | $8.79M | $6.03M | $4.00M | $4.67M | $5.82M | $101.7M |
| Total Operating Expenses | $9.02M | $17.88M | $18.56M | $38.83M | $14.22M | $11.60M | $54.97M | $62.92M | $8.26M | $105.8M |
| **Operating Income** | -$9.02M | -$17.88M | -$18.56M | -$38.83M | -$14.22M | -$9.59M | -$48.41M | -$62.92M | -$8.26M | -$105.8M |
| **EBITDA** | -$8.95M | -$17.75M | -$18.37M | -$38.64M | -$14.03M | -$9.43M | -$48.31M | -$62.87M | -$8.16M | -$105.6M |
| Interest Income | -- | -- | -- | -- | -- | -- | -- | -- | -$7.0K | $126K |
| Interest Expense | -$134K | -$537K | -$640K | $2.0K | $4.0K | $8.0K | $19K | $58K | -- | -- |
| Income Before Tax | -$8.83M | -$18.63M | -- | -- | -- | -$9.65M | -$48.17M | -$62.63M | -$7.49M | -$104.3M |
| Income Tax Expense | -- | -- | -- | -- | -- | -- | -- | -$13.58M | -$6.88M | -$29.39M |
| **Net Income** | -$8.83M | -$17.50M | -$17.98M | -$38.84M | -$14.19M | -$9.65M | -$48.17M | -$49.05M | -$613K | -$74.87M |
| Basic EPS | -$0.78 | -$1.72 | -$1.87 | -$4.77 | -$1.92 | -$2.04 | -$18.08 | -$20.96 | -$0.36 | -$38.08 |
| **Diluted EPS** | -$0.78 | -$1.72 | -$1.87 | -$4.77 | -$1.92 | -$2.04 | -$18.08 | -$20.96 | -$0.36 | -$39.52 |
| Basic Shares Outstanding | 11.3M | 10.2M | 9.7M | 8.1M | 614.9K | 4.6M | 2.7K | 2.3K | 2.0M | 2.0M |
| Diluted Shares Outstanding | 11.3M | 10.2M | 9.7M | 8.1M | 7.4M | 4.6M | 2.7K | 2.3K | 2.0M | 2.0M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $105K | $105K | $225K | -- | -- | -- | -- | -- |
| Research & Development | $1.98M | $2.14M | $1.37M | $1.62M | $954K | $1.12M | $1.36M | $2.04M |
| Total Operating Expenses | $3.59M | $3.29M | $2.58M | $2.48M | $2.09M | $2.11M | $2.34M | $3.23M |
| **Operating Income** | -$3.49M | -$3.18M | -$2.36M | -$2.48M | -$2.09M | -$2.11M | -$2.34M | -$3.23M |
| **EBITDA** | -$3.48M | -$3.17M | -$2.34M | -$2.47M | -$2.08M | -$2.09M | -$2.32M | -$3.20M |
| Interest Expense | -$15K | -$10K | -$22K | -$47K | -$22K | -$28K | -$37K | -$55K |
| Income Tax Expense | $0 | $0 | $0 | -- | -- | -- | -- | -- |
| **Net Income** | -$3.44M | -$3.16M | -$2.30M | -$2.43M | -$2.05M | -$2.06M | -$2.30M | -$3.27M |
| Basic EPS | -$0.20 | -$0.23 | -$0.17 | -- | -$0.19 | -$0.20 | -$0.23 | -- |
| **Diluted EPS** | -$0.20 | -$0.23 | -$0.17 | -- | -$0.19 | -$0.20 | -$0.23 | -- |
| Basic Shares Outstanding | 17.4M | 13.8M | 13.8M | -- | 11.0M | 10.2M | 10.2M | -- |
| Diluted Shares Outstanding | 17.4M | 13.8M | 13.8M | -- | 11.0M | 10.2M | 10.2M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $7.03M | $9.86M | $26.35M | $37.14M | $58.70M | $33.01M | $7.42M | $2.72M | $748K | $3.60M |
| **Cash & Short-Term Investments** | $7.03M | $9.86M | $26.35M | $37.14M | $58.70M | $33.01M | $7.42M | $2.72M | $748K | $3.60M |
| Accounts Receivable, Net | -- | -- | -- | -- | -- | $556K | $644K | -- | $1.0K | $21K |
| **Total Current Assets** | $8.13M | $11.58M | $29.09M | $40.18M | $59.32M | $34.02M | $8.28M | $2.94M | $2.18M | $5.47M |
| Property, Plant & Equipment, Net | $93K | $153K | $271K | $342K | $453K | $591K | $431K | $384K | $119K | $280K |
| Goodwill | -- | -- | -- | -- | $19.09M | $19.09M | $19.09M | $65.19M | $65.19M | $65.19M |
| **Total Non-Current Assets** | $1.58M | $1.88M | $2.17M | $662K | $20.07M | $20.23M | $20.25M | $65.62M | $119.2M | $119.4M |
| **Total Assets** | $9.71M | $13.46M | $31.26M | $40.84M | $79.39M | $54.24M | $28.53M | $68.56M | $121.4M | $124.9M |
| Accounts Payable | $890K | $1.54M | $1.22M | $614K | $578K | $657K | $1.51M | $616K | $494K | -- |
| **Total Current Liabilities** | $2.21M | $2.43M | $3.26M | $1.22M | $1.54M | $1.36M | $2.29M | $1.56M | $1.44M | $2.04M |
| **Total Non-Current Liabilities** | $1.17M | $1.50M | $1.61M | $57K | $298K | $379K | $537K | $117K | $14.59M | $20.52M |
| **Total Liabilities** | $3.38M | $3.93M | $4.88M | $1.27M | $1.84M | $1.74M | $2.82M | $1.67M | $16.03M | $22.56M |
| **Total Debt (incl. Leases)** | $1.50M | $1.81M | $1.85M | $297K | $534K | $597K | $817K | $331K | -- | -- |
| Common Stock | $13K | $10K | $10K | $8.0K | $8.0K | $71K | $36K | $30K | $24K | $24K |
| Retained Earnings | -$342.2M | -$333.4M | -$315.9M | -$297.9M | -$259.1M | -$244.9M | -$235.3M | -$187.1M | -$138.0M | -$137.4M |
| **Total Stockholders' Equity** | $6.33M | $9.52M | $26.38M | $39.60M | $77.55M | $52.51M | $25.71M | $66.89M | $105.4M | $102.3M |
| Total Equity | $6.33M | $9.52M | $26.38M | $39.60M | $77.55M | $52.51M | $25.71M | $66.89M | $105.4M | $102.3M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $4.87M | $2.17M | $4.68M | $7.03M | $7.73M | $4.77M | $6.92M | $9.86M |
| **Cash & Short-Term Investments** | $4.87M | $2.17M | $4.68M | $7.03M | $7.73M | $4.77M | $6.92M | $9.86M |
| **Total Current Assets** | $5.51M | $3.24M | $5.94M | $8.13M | $8.78M | $6.76M | $8.83M | $11.58M |
| Property, Plant & Equipment, Net | $59K | $69K | $81K | $93K | $106K | $107K | $127K | $153K |
| **Total Non-Current Assets** | $1.26M | $1.41M | $1.49M | $1.58M | $1.66M | $1.74M | $1.83M | $1.88M |
| **Total Assets** | $6.77M | $4.65M | $7.43M | $9.71M | $10.45M | $8.51M | $10.66M | $13.46M |
| Accounts Payable | $2.30M | $1.89M | $1.37M | $890K | $745K | $856K | $808K | $1.54M |
| **Total Current Liabilities** | $3.20M | $2.62M | $2.23M | $2.21M | $1.52M | $1.83M | $1.93M | $2.43M |
| **Total Non-Current Liabilities** | $896K | $989K | $1.08M | $1.17M | $1.26M | $1.34M | $1.42M | $1.50M |
| **Total Liabilities** | $4.10M | $3.60M | $3.31M | $3.38M | $2.78M | $3.17M | $3.35M | $3.93M |
| **Total Debt (incl. Leases)** | $1.26M | $1.34M | $1.42M | $1.50M | $1.58M | $1.66M | $1.73M | $1.81M |
| Common Stock | $19K | $13K | $13K | $13K | $13K | $10K | $10K | $10K |
| Retained Earnings | -$351.2M | -$347.7M | -$344.5M | -$342.2M | -$339.8M | -$337.8M | -$335.7M | -$333.4M |
| **Total Stockholders' Equity** | $2.67M | $1.04M | $4.12M | $6.33M | $7.67M | $5.33M | $7.30M | $9.52M |
| Total Equity | $2.67M | $1.04M | $4.12M | $6.33M | $7.67M | $5.33M | $7.30M | $9.52M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$8.83M | -$17.50M | -$17.98M | -$38.84M | -$14.19M | -$9.65M | -$48.17M | -$49.05M | -$613K | -$74.87M |
| Depreciation & Amortization | $72K | $126K | $189K | $185K | $190K | $157K | $98K | $50K | $101K | $201K |
| Stock-Based Compensation | $270K | $643K | $801K | $855K | $724K | $662K | $351K | $562K | $614K | $548K |
| Change in Receivables | -- | -- | -- | -- | $556K | $88K | -$644K | -- | $20K | $11K |
| **Operating Cash Flow** | -$8.19M | -$16.48M | -$14.67M | -$21.43M | -$12.72M | -$9.83M | -$1.56M | -$8.29M | -$6.90M | -$14.65M |
| Capital Expenditure | -$12K | -$8.0K | -$118K | -$74K | -$52K | -$240K | -$145K | -$28K | -$40K | -$51K |
| **Free Cash Flow** | -$8.20M | -$16.49M | -$14.78M | -$21.51M | -$12.77M | -$10.07M | -$1.71M | -$8.32M | -$6.94M | -$14.71M |
| **Investing Cash Flow** | -$12K | -$8.0K | -$118K | -$74K | -$52K | -$240K | -$145K | $1.37M | -$40K | $3.0K |
| Common Stock Issued | $154K | -- | $4.00M | -- | $38.51M | $35.78M | $6.64M | $7.68M | $3.00M | $9.01M |
| **Financing Cash Flow** | $5.37M | -- | $3.99M | -$27K | $38.47M | $35.66M | $6.42M | $8.89M | $4.08M | $9.02M |
| **Net Change in Cash** | -$2.83M | -$16.49M | -$10.79M | -$21.54M | $25.70M | $25.59M | $4.72M | $1.98M | -$2.86M | -$5.64M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$3.44M | -$3.16M | -$2.30M | -$2.43M | -$2.05M | -$2.06M | -$2.30M | -$3.27M |
| Depreciation & Amortization | $10K | $12K | $12K | $13K | $13K | $21K | $25K | $28K |
| Stock-Based Compensation | $74K | $92K | $84K | $56K | $48K | $84K | $82K | $85K |
| **Operating Cash Flow** | -$2.30M | -$2.52M | -$2.34M | -$1.74M | -$1.36M | -$2.15M | -$2.94M | -$3.16M |
| Capital Expenditure | -- | -- | -- | -- | -- | -- | -- | $0 |
| **Free Cash Flow** | -- | -- | -- | -- | -- | -- | -- | -$3.16M |
| **Investing Cash Flow** | -- | -- | -- | -- | -- | -- | -- | $0 |
| **Net Change in Cash** | $2.70M | -$2.52M | -$2.34M | -$704K | $2.96M | -$2.15M | -$2.94M | -$3.16M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -- | -- | -- | -- | -- | -476.0% | -737.4% | -- | -- | -- |
| **Net Profit Margin** | -- | -- | -- | -- | -- | -479.0% | -733.8% | -- | -- | -- |
| Return on Equity (ROE) | -139.5% | -183.8% | -68.2% | -98.1% | -18.3% | -18.4% | -187.4% | -73.3% | -0.6% | -73.2% |
| Return on Assets (ROA) | -90.9% | -130.1% | -57.5% | -95.1% | -17.9% | -17.8% | -168.8% | -71.5% | -0.5% | -60.0% |
| Current Ratio | 3.68x | 4.77x | 8.92x | 33.04x | 38.40x | 25.05x | 3.62x | 1.89x | 1.51x | 2.68x |
| Quick Ratio | 3.18x | 4.06x | 8.08x | 30.55x | 38.00x | 24.72x | 3.53x | 1.75x | 0.52x | 1.78x |
| Debt to Equity | 0.24x | 0.19x | 0.07x | 0.01x | 0.01x | 0.01x | 0.03x | 0.00x | -- | -- |
| **Revenue Growth (YoY)** | -- | -- | -- | -- | -- | -69.3% | -- | -- | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -423.7% | -951.9% | -214.5% | -139.5% | -126.1% | -235.5% | -217.0% | -183.8% |
| Return on Assets (ROA) | -167.3% | -213.8% | -118.9% | -90.9% | -92.6% | -147.7% | -148.7% | -130.1% |
| Current Ratio | 1.72x | 1.24x | 2.66x | 3.68x | 5.78x | 3.69x | 4.57x | 4.77x |
| Quick Ratio | 1.52x | 0.83x | 2.10x | 3.18x | 5.08x | 2.60x | 3.58x | 4.06x |
| Debt to Equity | 0.47x | 1.29x | 0.35x | 0.24x | 0.21x | 0.31x | 0.24x | 0.19x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
